PEAK-1
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
- NCT07011719 ↗
- Recruiting
- Arcus Biosciences, Inc.
- Deep
We haven't built an HCP commentary report on PEAK-1 (casdatifan plus cabozantinib in advanced clear cell renal cell carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Questions raised in the commentary
Automated from the 36 newest of 49 indexed sources (Oct 2024 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.
- Whether adding casdatifan improves outcomes beyond cabozantinib
- How anemia and hypoxia may affect tolerability of casdatifan plus cabozantinib
- How PEAK-1 may shape treatment sequencing after immunotherapy
Also discussed: other HIF-2α inhibitor combinations.
Indexed commentary on PEAK-1 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 36 | |
| YouTube | 11 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Metastatic Clear Cell Renal Cell Carcinoma; Advanced Clear Cell Renal Cell Carcinoma
- Interventions
- Casdatifan; Cabozantinib; Placebo
- Arms
- Arm A (Experimental Arm) · Experimental
- Arm B (Comparator Arm) · Placebo comparator
- Enrollment
- 720 (estimated)
- Primary outcomes
- Progression-free Survival (PFS) as assessed by Blinded Independent Central Review (BICR) according to RECIST 1.1
- Sponsor
- Arcus Biosciences, Inc.
- Start
- Sep 8, 2025
- Primary completion
- Apr 2028 (estimated)
- Results posted
- No
- Registry record
- NCT07011719 · updated Oct 26, 2026
Publications
linked from the registry- Mailyan AK, Mata G, Beatty JW, Drew SL, Fournier J, Yu K, Gal B, Kalisiak J, Yan X, Tran A, Su Y, Rosen BR, Jeffrey JL, Hardman C, Epplin M, Ginn E, Sun M, Chen A, Fabila P, Sivick KE, Schweickert PG, Piovesan D, Meleza C, Pham AT, Chen PY, Jin L, Walters MJ, Walker NP, Kwon HJ, Leleti MR, Powers JP, Lawson KV. Discovery of Casdatifan, Part II: A Potent and Orally Bioavailable Inhibitor of Hypoxia Inducible Factor-2alpha. J Med Chem. 2026 Jun 25;69(12):14952-14988. doi: 10.1021/acs.jmedchem.5c03724. Epub 2026 Jun 5. PubMed 42246926